Agilent Technologies Inc. has announced the FDA approval of its MMR IHC Panel pharmDx (Dako Omnis) as a companion diagnostic test for colorectal cancer. This newly approved test aids in identifying mismatch repair deficient (dMMR) colorectal cancer patients who can be treated with Bristol Myers Squibb's immunotherapy drugs, Opdivo® (nivolumab) and Yervoy® (ipilimumab). Developed in collaboration with Bristol Myers Squibb, the test is the only FDA-approved companion diagnostic IHC panel specifically for detecting dMMR in colorectal cancer patients, allowing healthcare providers to better tailor immunotherapy treatments and potentially improve patient outcomes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.